2023
DOI: 10.1002/ijc.34753
|View full text |Cite
|
Sign up to set email alerts
|

Differences in time to patient access to innovative cancer medicines in six European countries

Julie M. Vancoppenolle,
Nora Franzen,
Simone N. Koole
et al.

Abstract: Patients across Europe face inequity regarding access to anticancer medicines. While access is typically evaluated through reimbursement status or sales data, patients can receive first access through early access programs (EAPs) or off‐label use. This study aims to assess the time to patient access at the hospital level, considering different indications and countries. (Pre‐)registered access to six innovative medicines (Olaparib, Niraparib, Ipilimumab, Osimeritinib, Nivolumab and Ibritunib) was measured usin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 42 publications
(79 reference statements)
1
0
0
Order By: Relevance
“…Furthermore, the ODs provided in those regions outnumber the remaining regions. This is in line with the results of a recent study by Vancoppenolle et al [77], in which patient access to specialized hospitals was significantly accelerated. However, several studies contradict the centralized approach, arguing that the "hub and spoke" model is more appropriate.…”
Section: Discussionsupporting
confidence: 92%
“…Furthermore, the ODs provided in those regions outnumber the remaining regions. This is in line with the results of a recent study by Vancoppenolle et al [77], in which patient access to specialized hospitals was significantly accelerated. However, several studies contradict the centralized approach, arguing that the "hub and spoke" model is more appropriate.…”
Section: Discussionsupporting
confidence: 92%